What is the prevalence of VACTERL/VATER association?
How many people does VACTERL/VATER association affect? Does it have the same prevalence in men and women? And in the different countries?
The prevalence of VACTERL/VATER association is estimated to be around 1 in 10,000 to 1 in 40,000 live births. It is a rare condition characterized by the presence of multiple congenital anomalies affecting various organ systems. The acronym VACTERL stands for vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities. The exact cause of VACTERL/VATER association is unknown, but it is believed to result from a combination of genetic and environmental factors. Early diagnosis and multidisciplinary management are crucial for optimizing outcomes in affected individuals.
VACTERL/VATER association is a rare congenital disorder characterized by the presence of multiple birth defects. It is an acronym that stands for vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities. The exact cause of VACTERL/VATER association is unknown, but it is believed to result from a combination of genetic and environmental factors.
The prevalence of VACTERL/VATER association is estimated to be around 1 in 10,000 to 1 in 40,000 live births. However, the actual prevalence may be higher as some cases may go undiagnosed or unreported. The condition affects both males and females equally and has been reported in various ethnic groups worldwide.
Diagnosis of VACTERL/VATER association is based on the presence of at least three of the characteristic features. The severity and combination of defects can vary widely among affected individuals, making it a complex and challenging condition to manage.
Treatment for VACTERL/VATER association typically involves a multidisciplinary approach, with interventions tailored to address the specific defects present in each individual. Early detection, comprehensive medical care, and ongoing support are crucial for optimizing outcomes and improving the quality of life for those affected by this condition.
